Please wait while the formulary information is being retrieved.
PREVYMIS (LETERMOVIR)
- Prevention of cytomegalovirus infection after allo-HSCT
240 mg tablet
- 2 tablets (480 mg) by oral route once daily
480 mg tablet
- 1 tablet (480 mg) by oral route once daily
240 mg/12 mL intravenous solution
- Infuse 480 mg over 1 hour(s) by intravenous route once daily
480 mg/24 mL intravenous solution
- Infuse 480 mg over 1 hour(s) by intravenous route once daily
Prevention of cytomegalovirus infection after allo-HSCT
- Infuse 240 mg over 1 hour(s) by intravenous route once daily
- Infuse 480 mg over 1 hour(s) by intravenous route once daily
- 1 tablet (240 mg) by oral route once daily
- 2 tablets (480 mg) by oral route once daily
- 1 tablet (480 mg) by oral route once daily
- Juxtapid
- lomitapide
Contraindicated
- Bosulif
- bosutinib
- colchicine
- colchicine-probenecid
- Colcrys
- guanfacine
- ibrutinib
- Imbruvica
- Intuniv Er
- Olysio
- Samsca
- simeprevir
- Tenex
- tolvaptan
Severe
Moderate
- Abstral
- Actiq
- Afinitor
- Afinitor Disperz
- Alfenta
- alfentanil
- Anti-diarrhea
- Anti-diarrheal (lope)-anti-gas
- Anti-diarrheal (loperamide)
- avanafil
- bosentan
- cilostazol
- Diamode
- Duragesic
- Endocet
- Endodan
- eplerenone
- everolimus
- fentanyl
- fentanyl citrate
- fentanyl citrate (PF)
- Fentora
- ibuprofen-oxycodone
- Imodium Multi-symptom Relief
- Inspra
- ivacaftor
- Kalydeco
- Lazanda
- Levitra
- Lo-peramide
- loperamide
- loperamide-simethicone
- Oxecta
- oxycodone
- oxycodone-acetaminophen
- oxycodone-aspirin
- Oxycontin
- Percocet
- Percodan
- Pletal
- Primlev
- Roxicet
- Stendra
- Sublimaze (pf)
- Subsys
- Tracleer
- Ultra A-d
- vardenafil
- Xartemis Xr
- Zortress
- None
Contraindicated
- Severe hepatic disease
Severe
Moderate
- None
PREVYMIS (LETERMOVIR)
- Prevention of cytomegalovirus infection after allo-HSCT
- None
- Acute abdominal pain
- Cough
- Diarrhea
- Fatigue
- Headache disorder
- Nausea
- Peripheral edema
- Vomiting
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Dyspnea
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Letermovir
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Letermovir
- Severity Level:
2
- Additional Notes: Insufficient human data avail; consider maternal benefits vs poss fetal risks
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Letermovir
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Prevention of cytomegalovirus infection after allo-HSCT | |
| Z94.84 | Stem cells transplant status |
| 0-9 | A-Z |
|---|---|
| Z94.84 | Stem cells transplant status |
Formulary Reference Tool